Table 1.
Baseline Characteristics Among Patients With Metastatic NSCLC
| Characteristic | No. of Patients(N = 1,574) | % |
|---|---|---|
| Demographic characteristics | ||
| Age at diagnosis, years | ||
| 21-54 | 205 | 13 |
| 55-64 | 389 | 25 |
| 65-74 | 539 | 34 |
| 75+ | 441 | 28 |
| Sex | ||
| Male | 1,022 | 65 |
| Female | 552 | 35 |
| Marital status | ||
| Married/living as married | 933 | 59 |
| Not married | 623 | 40 |
| Unknown | 18 | 1 |
| Race | ||
| White | 1,122 | 71 |
| Hispanic/Latino | 74 | 5 |
| African American | 222 | 14 |
| Asian/Pacific Islander | 78 | 5 |
| Other | 72 | 5 |
| Unknown | 6 | 0.4 |
| Insurance | ||
| Medicare | 263 | 17 |
| Medicaid | 158 | 10 |
| Medicare plus private | 539 | 34 |
| Private | 387 | 25 |
| Other | 212 | 13 |
| Unknown | 15 | 1 |
| Clinical characteristics | ||
| Comorbidity score* | ||
| None | 326 | 21 |
| Mild | 581 | 37 |
| Moderate | 335 | 21 |
| Severe | 332 | 21 |
| Chemotherapy after metastasis | ||
| No | 770 | 49 |
| Yes | 804 | 51 |
| Primary lung cancer–directed surgery after metastasis | ||
| No | 1,474 | 94 |
| Yes | 100 | 6 |
| Metastatic site surgery† | ||
| No | 1,480 | 94 |
| Yes | 94 | 6 |
| Provider characteristics | ||
| Integrated network | ||
| No | 919 | 58 |
| Yes | 655 | 42 |
| PDCR site | ||
| Cancer Research Network | 218 | 14 |
| Northern California | 322 | 20 |
| Alabama | 192 | 12 |
| Los Angeles | 235 | 15 |
| Iowa | 336 | 21 |
| Veterans Administration | 271 | 17 |
Abbreviation: NSCLC, non–small-cell lung cancer; PDCR, Primary Data Collection and Research.
*
Defined by using the Adult Comorbidity Evaluation 27, a validated medical record-based system that assigns each patient a four-category comorbidity score (none, mild, moderate, or severe) based on severity noted across multiple body systems, from 3 months prior to diagnosis to initial treatment.
†
Includes surgery to brain, bone, liver, or adrenal glands.